LINC00152 has been described to repress gene expression by interacting with EZH2 [40] as well as to activate the transcription of EpCAM by binding to its promoter, thereby favoring cell proliferation in hepatoma cells [41]. Here, EZH2 is linked to hepatocellular carcinoma.